These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Inhibition of allograft rejection by anti-T-cell receptor-alpha beta monoclonal antibodies preserving resistance to bacterial infection. Eto M; Yoshikai Y; Nishimura Y; Hiromatsu K; Maeda T; Nomoto K; Kong YY; Kubo RT; Kumazawa J; Nomoto K Immunology; 1994 Feb; 81(2):198-204. PubMed ID: 8157269 [TBL] [Abstract][Full Text] [Related]
23. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506 [TBL] [Abstract][Full Text] [Related]
24. Fibrinoid necrosis of a temporal artery complicating the treatment of refractory cardiac allograft rejection with murine monoclonal CD3 antibody (OKT3). Hammond EH; Watson FS; Bristow MR; O'Connell JB; Gilbert EM; Doty DB; Renlund DG J Heart Transplant; 1990; 9(3 Pt 1):236-8. PubMed ID: 2113090 [TBL] [Abstract][Full Text] [Related]
31. The reuse of OKT3 after previous rejection or induction therapy in cadaveric renal transplantation. Shield CF; Hughes JD Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):35-8. PubMed ID: 2510509 [TBL] [Abstract][Full Text] [Related]
32. Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human alpha/beta-T cell receptor. Knight RJ; Kurrle R; McClain J; Racenberg J; Baghdahsarian V; Kerman R; Lewis R; van Buren CT; Kahan BD Transplantation; 1994 Jun; 57(11):1581-8. PubMed ID: 8009591 [TBL] [Abstract][Full Text] [Related]
33. Treatment with OKT3 and cyclosporine for acute allograft rejection. Schulak JA; Mayes JT; Hricik DE Transplant Proc; 1991 Aug; 23(4):2119-22. PubMed ID: 1908150 [TBL] [Abstract][Full Text] [Related]
34. Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation. Kormos RL; Herlan DB; Armitage JM; Stein K; Kaufman C; Zeevi A; Duquesnoy R; Hardesty RL; Griffith BP J Heart Transplant; 1990; 9(1):1-9, discussion 9-10. PubMed ID: 2107288 [TBL] [Abstract][Full Text] [Related]
35. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients. Herzberg GZ; Rossi AF; Courtney M; Gelb BD J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760 [TBL] [Abstract][Full Text] [Related]
36. Prophylactic OKT3 used as induction therapy for heart transplantation. Starnes VA; Oyer PE; Stinson EB; Dein JR; Shumway NE Circulation; 1989 Nov; 80(5 Pt 2):III79-83. PubMed ID: 2509108 [TBL] [Abstract][Full Text] [Related]
37. Unique antithymocyte serum versus OKT3 for induction immunotherapy after heart transplantation. Frist WH; Merrill WH; Eastburn TE; Atkinson JB; Stewart JR; Hammon JW; Bender JW J Heart Transplant; 1990; 9(5):489-94. PubMed ID: 2121921 [TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibody treatment of human allograft recipients. Delmonico FL; Cosimi AB Surg Gynecol Obstet; 1988 Jan; 166(1):89-98. PubMed ID: 3276014 [TBL] [Abstract][Full Text] [Related]